Systematic review on oncologic outcomes on adjuvant endovesical treatment for non-muscle invasive bladder cancer in patients with solid organ transplant.
BCG
Bladder cancer
Chemotherapy
Mitomycin
Transplanted patients
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
10
04
2022
accepted:
06
10
2022
pubmed:
12
11
2022
medline:
3
12
2022
entrez:
11
11
2022
Statut:
ppublish
Résumé
Urothelial carcinoma has a higher incidence in renal transplanted patients according to several registries (relative risk × 3), and the global prognosis is inferior to the general population. The potential impact of immunosuppressive therapy on the feasibility, efficacy, and complications of endovesical treatment, especially Bacillus Calmette-Guerin, has a low level of evidence. We performed a systematic review that aimed to assess the morbidity and oncological outcomes of adjuvant endovesical treatment in solid organ transplanted patients. Medline was searched up to December 2021 for all relevant publications reporting oncologic outcomes of endovesical treatment in solid organ transplanted patients with NMIBC. Data were synthesized in light of methodological and clinical heterogeneity. Twenty-three retrospective studies enrolling 238 patients were included: 206 (96%) kidney transplants, 5 (2%) liver transplants, and 2 (1%) heart transplants. Concerning staging: 25% were pTa, 62% were pT1, and 22% were CIS. 140/238 (59%) patients did not receive adjuvant treatment, 50/238 (21%) received mitomycin C, 4/238 (2%) received epirubicin, and 46/238 (19%) received BCG. Disease-free survival reached 35% with TURBT only vs. 47% with endovesical treatment (Chi-square test p = 0.08 OR 1.2 [0.98-1.53]). The complication rate of endovesical treatment was 12% and was all minor (Clavien-Dindo I). In solid organ transplanted patients under immunosuppressive treatment, both endovesical chemotherapy and BCG are safe, but the level of evidence concerning efficacy in comparison with the general population is low. According to these results, adjuvant treatment should be proposed for NMIC in transplanted patients as in the general population.
Identifiants
pubmed: 36367586
doi: 10.1007/s00345-022-04188-9
pii: 10.1007/s00345-022-04188-9
doi:
Substances chimiques
BCG Vaccine
0
Adjuvants, Immunologic
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2901-2910Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108
pubmed: 27370177
doi: 10.1016/j.eururo.2016.06.010
Professionals SO (2020) EAU guidelines: non-muscle-invasive bladder cancer [Internet]. Uroweb. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ . Accessed 05 Apr 2020
Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17):1891
pubmed: 22045767
pmcid: 3310893
doi: 10.1001/jama.2011.1592
Vajdic CM, van Leeuwen MT (2009) Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 125(8):1747–1754
pubmed: 19444916
doi: 10.1002/ijc.24439
Gaya SBM, Rees AJ, Lechler RI, Williams G, Mason PD (1995) Malignant disease in patients with long-term renal transplants. Transplantation 59(12):1705–1709
pubmed: 7604441
doi: 10.1097/00007890-199506270-00011
Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR et al (2009) De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87(9):1347–1359
pubmed: 19424035
doi: 10.1097/TP.0b013e3181a238f6
Ehdaie B, Stukenborg GJ, Theodorescu D (2009) Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol 182(4):1482–1487
pubmed: 19683766
doi: 10.1016/j.juro.2009.06.043
Ardelt PU, Rieken M, Ebbing J, Bonkat G, Vlajnic T, Bubendorf L et al (2016) Urothelial cancer in renal transplant recipients: incidence, risk factors, and oncological outcome. Urology 1(88):104–110
doi: 10.1016/j.urology.2015.10.031
Prabharasuth D, Moses KA, Bernstein M, Dalbagni G, Herr HW (2013) Management of bladder cancer after renal transplantation. Urology 81(4):813–819
pubmed: 23290344
doi: 10.1016/j.urology.2012.11.035
Yan L, Chen P, Chen EZ, Gu A, Jiang ZY (2014) Risk of bladder cancer in renal transplant recipients: a meta-analysis. Br J Cancer 110(7):1871–1877
pubmed: 24496458
pmcid: 3974078
doi: 10.1038/bjc.2014.44
Liu S, Chaudhry MR, Berrebi AA, Papadimitriou JC, Drachenberg CB, Haririan A et al (2017) Polyomavirus replication and smoking are independent risk factors for bladder cancer after renal transplantation. Transplantation 101(6):1488–1494
pubmed: 27232933
doi: 10.1097/TP.0000000000001260
Shinohara T, Matsuda M, Cheng SH, Marshall J, Fujita M, Nagashima K (1993) BK virus infection of the human urinary tract. J Med Virol 41(4):301–305
pubmed: 8106863
doi: 10.1002/jmv.1890410408
Husain E, Prowse DM, Ktori E, Shaikh T, Yaqoob M, Junaid I et al (2009) Human papillomavirus is detected in transitional cell carcinoma arising in renal transplant recipients. Pathology 41(3):245–247
pubmed: 19291536
doi: 10.1080/00313020902756303
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196
pubmed: 19638912
doi: 10.1097/SLA.0b013e3181b13ca2
Mitropoulos D, Artibani W, Biyani CS, Bjerggaard Jensen J, Rouprêt M, Truss M (2018) Validation of the Clavien-Dindo grading system in urology by the european association of urology guidelines ad Hoc panel. Eur Urol Focus 4(4):608–613
pubmed: 28753862
doi: 10.1016/j.euf.2017.02.014
Rodríguez Faba O, Breda A, Gausa L, Palou J, Villavicencio H (2015) Tumores urológicos de novo en pacientes trasplantados renales. Actas Urol Esp 39(2):122–127
pubmed: 24996779
doi: 10.1016/j.acuro.2014.05.002
Kamal MM, Soliman SM, Shokeir AA, Abol-Enein H, Ghoneim MA (2007) Bladder carcinoma among live-donor renal transplant recipients: a single-centre experience and a review of the literature. BJU Int. https://doi.org/10.1111/j.1464-410X.2007.07210.x
doi: 10.1111/j.1464-410X.2007.07210.x
pubmed: 17850360
Medani S, O’Kelly P, O’Brien KM, Mohan P, Magee C, Conlon P (2014) Bladder cancer in renal allograft recipients: risk factors and outcomes. Transplant Proc 46(10):3466–3473
pubmed: 25498074
doi: 10.1016/j.transproceed.2014.06.075
Cox J, Colli JL (2011) Urothelial cancers after renal transplantation. Int Urol Nephrol 43(3):681–686
pubmed: 21373847
doi: 10.1007/s11255-011-9907-z
Palazzetti A, Bosio A, Dalmasso E, Destefanis P, Fop F, Pisano F et al (2018) De Novo bladder urothelial neoplasm in renal transplant recipients: a retrospective, multicentered study. Urol Int 100(2):185–192
pubmed: 29342465
doi: 10.1159/000481917
Swietek N, Waldert M, Susani M, Schatzl G, Klatte T (2013) Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation. Wien Klin Wochenschr 125(7–8):189–195
pubmed: 23536017
doi: 10.1007/s00508-013-0343-1
Ederer IA, Lucca I, Hofbauer SL, Haidinger M, Haitel A, Susani M et al (2015) Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. World J Urol 33(12):2087–2093
pubmed: 25860378
doi: 10.1007/s00345-015-1554-z
Roumeguère T, Broeders N, Jayaswal A, Rorive S, Quackels T, Pozdzik A et al (2015) Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int 28(2):199–205
pubmed: 25377421
doi: 10.1111/tri.12484
Herr HW, Dalbagni G (2013) Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer: Intravesical BCG in immunologically compromised patients. BJU Int 111(6):984–987
pubmed: 23351086
doi: 10.1111/j.1464-410X.2012.11778.x
Rogers A, Ng JK, Glendinning J, Rix D (2012) The management of transitional cell carcinoma (TCC) in a European regional renal transplant population. BJU Int 110(2 Pt 2):E34–E40
pubmed: 22243691
doi: 10.1111/j.1464-410X.2011.10777.x
Wang HB, Hsieh HH, Chen YT, Chiang CY, Cheng YT (2002) The outcome of post-transplant transitional cell carcinoma in 10 renal transplant recipients. Clin Transplant 16(6):410–413
pubmed: 12437619
doi: 10.1034/j.1399-0012.2002.01152.x
Neuzillet Y, Davin JL, Lechevallier E (2006) Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 16(1):32–35
Dhanani NN, Kamat AM (2006) Treatment of bladder cancer in cardiac transplant patients. Int Urol Nephrol 38(3–4):477–479
pubmed: 17115247
Palou J, Angerri O, Segarra J, Caparrós J, Guirado L, Diaz JM et al (2003) Intravesical bacillus calmette-gueÈrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 76(10):1514–1516
pubmed: 14657696
doi: 10.1097/01.TP.0000090748.32764.0F
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL et al (2015) Maintenance therapy with 3-monthly Bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 68(2):256–262
pubmed: 25794457
doi: 10.1016/j.eururo.2015.02.040
Yu J, Lee CU, Kang M, Jeon HG, Jeong BC, Seo SI et al (2018) Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients. Cancer Manag Res 11:157–166
pubmed: 30636892
pmcid: 6307682
doi: 10.2147/CMAR.S185796
Tomaszewski JJ, Larson JA, Smaldone MC, Hayn MH, Jackman SV (2011) Management of bladder cancer following solid organ transplantation. Adv Urol 2011:1–7
doi: 10.1155/2011/256985
Elkentaoui H, Robert G, Pasticier G, Bernhard JC, Couzi L, Merville P et al (2010) Therapeutic management of De Novo urological malignancy in renal transplant recipients: the experience of the french department of urology and kidney transplantation from Bordeaux. Urology 75(1):126–132
pubmed: 19864001
doi: 10.1016/j.urology.2009.06.106
Zhou M, Zhu Y, Wang L, Wang Y, Fu S, Min Z (2006) Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases. Clin Transpl 4:395–398
Tillou X, Raynal G, Limani K, Saint F, Petit J (2008) Carcinome in situ vésical et urétral chez un patient transplanté rénal : échec de la BCG thérapie. Prog En Urol 18(13):1097–1099
doi: 10.1016/j.purol.2008.08.002
Ranasinghe WKB, Suh N, Hughes PD (2016) Survival outcomes in renal transplant recipients with renal cell carcinoma or transitional cell carcinoma from the ANZDATA database. Exp Clin Transpl 14(2):166–171
Pradere B, Schuettfort V, Mori K, Quhal F, Aydh A, Sari MR (2020) Management of de-novo urothelial carcinoma in transplanted patients. Curr Opin Urol 30(3):467–474
pubmed: 32235285
doi: 10.1097/MOU.0000000000000749
Moonen PMJ, Bakkers JMJE, Kiemeney LALM, Schalken JA, Melchers WJG, Witjes JA (2007) Human Papilloma Virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 52(2):464–469
pubmed: 17116360
doi: 10.1016/j.eururo.2006.11.017
Xiao J, Zhu X, Hao GY, Zhu YC, Ma LL, Zhang YH et al (2011) Association between urothelial carcinoma after renal transplantation and infection by human papillomavirus types 16 and 18. Transplant Proc 43(5):1638–1640
pubmed: 21693249
doi: 10.1016/j.transproceed.2011.03.053
Ziegler J, Ho J, Gibson IW, Nayak JG, Stein M, Walkty A et al (2018) Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transpl Infect Dis 20(5):e12931
pubmed: 29809299
doi: 10.1111/tid.12931
Caravaca-Fontán F, Cano Megías M, Sánchez-Conde M, Elías Triviño S, Fernández-Rodríguez A, Liaño F (2016) Subacute interstitial pneumonitis due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin instillation in a renal transplant patient. Nefrol Engl Ed 36(6):711–713
Antunes H, Tavares-da-Silva E, Oliveira R, Carvalho J, Parada B, Bastos C et al (2018) De Novo urologic malignancies in renal transplant recipients. Transpl Proc 50(5):1348–1354
doi: 10.1016/j.transproceed.2018.02.086
Lenis AT, Lec PM, Chamie K, Mshs M (2020) Bladder cancer: a review. JAMA 324(19):1980
pubmed: 33201207
doi: 10.1001/jama.2020.17598
Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183
pubmed: 820877
doi: 10.1016/S0022-5347(17)58737-6
Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM et al (2020) Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS.” Eur Urol 78(5):690–698
pubmed: 32446864
doi: 10.1016/j.eururo.2020.04.066
Liem EIML, Crezee H, de la Rosette JJ, de Reijke TM (2016) Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperth 32(4):363–373
doi: 10.3109/02656736.2016.1155760
Tan WP, Longo T, Inman BA (2020) Heated intravesical chemotherapy: biology and clinical utility. Urol Clin N Am 47(1):55–72
doi: 10.1016/j.ucl.2019.09.008
Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non–muscle-invasive bladder cancer. Eur Urol 69(6):1046–1052
pubmed: 26803476
doi: 10.1016/j.eururo.2016.01.006
Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21(23):4270–4276
pubmed: 14581436
doi: 10.1200/JCO.2003.01.089
Boissier R, Delaporte V, Legris T, Moal V, Lechevallier E (2020) Pelvic surgery in the transplant recipient: important considerations for the non-transplant surgeon. Curr Urol Rep 21(1):2
pubmed: 31960158
doi: 10.1007/s11934-020-0954-9